Pancreatic Cancer Research

ResearcherUniversity of Southern CaliforniaActive in the last 2 years

Heinz‐Josef Lenz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2178-9568; OpenAlex author ID A5045441776. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 3 papers

Papers 15

  1. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  2. Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study. Co-author DOI 10.1016/j.xcrm.2023.101391↗
  3. Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study. Co-author DOI 10.1016/j.xcrm.2024.101842↗
  4. Rising Incidence and Racial Disparities of Early-Onset Pancreatic Cancer in the United States, 1995-2018. Co-author DOI 10.1053/j.gastro.2022.03.011↗
  5. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  6. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  7. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  8. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  9. Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. Co-author DOI 10.3390/cancers10040095↗
  10. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Co-author DOI 10.1007/s10147-014-0730-2↗
  11. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.2015.62.8719↗
  12. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized … Co-author DOI 10.1002/cncr.28744↗
  13. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Last author DOI 10.1007/s10637-011-9658-9↗
  14. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinom… Co-author DOI 10.1007/s10637-011-9691-8↗
  15. Pancreatic cancer: medical management (novel chemotherapeutics). Last author DOI 10.1016/j.gtc.2011.12.004↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Z. Huang · 3 shared papers, 2022–2024 · strength 0.55
  2. Veronica Wendy Setiawan · 3 shared papers, 2022–2024 · strength 0.55
  3. Steven R. Grossman · 3 shared papers, 2022–2024 · strength 0.55
  4. Samantha A. Streicher · 2 shared papers, 2024 · strength 0.40
  5. Lang Wu · 2 shared papers, 2024 · strength 0.40
  6. Hajime Yamazaki · 2 shared papers, 2024 · strength 0.40
  7. Andreas Seeber · 3 shared papers, 2020–2024 · strength 0.36
  8. Anthony Frank Shields · 3 shared papers, 2020–2024 · strength 0.36
  9. Emil Lou · 2 shared papers, 2022–2024 · strength 0.28
  10. Wafik S. El‐Deiry · 2 shared papers, 2020–2024 · strength 0.26
  11. Stephen Jacob Pandol · 2 shared papers, 2018–2022 · strength 0.22
  12. Safi Shahda · 2 shared papers, 2020 · strength 0.20
  13. Bert H. O’Neil · 2 shared papers, 2020 · strength 0.20
  14. Efrat Dotan · 2 shared papers, 2020 · strength 0.20
  15. Dana Backlund Cardin · 2 shared papers, 2020 · strength 0.20
  16. Steven J. Cohen · 2 shared papers, 2020 · strength 0.20
  17. Wells A. Messersmith · 2 shared papers, 2020 · strength 0.20
  18. Florian Kocher · 2 shared papers, 2020–2022 · strength 0.19
  19. Alberto Puccini · 2 shared papers, 2020–2022 · strength 0.19
  20. Richard M. Goldberg · 2 shared papers, 2020–2022 · strength 0.19
  21. Michael J. Hall · 2 shared papers, 2020–2022 · strength 0.19
  22. Wolfgang Michael Korn · 2 shared papers, 2020–2022 · strength 0.19
  23. John Lindsay Marshall · 2 shared papers, 2020–2022 · strength 0.19
  24. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.17
  25. Sepideh Gholami · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.